<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856309</url>
  </required_header>
  <id_info>
    <org_study_id>CR102023</org_study_id>
    <secondary_id>CNTO136ARA3004</secondary_id>
    <secondary_id>2012-001176-10</secondary_id>
    <nct_id>NCT01856309</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003</brief_title>
  <acronym>SIRROUND-LTE</acronym>
  <official_title>A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136
      (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment
      with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, long-term study of sirukumab (CNTO 136) that will be conducted in two
      groups of participants at the same time (parallel-group study). The maximum duration of
      participation in this study is 208 weeks, followed by approximately 16 weeks of safety and
      efficacy follow-up after the administration of the final study agent injection of sirukumab.
      Participant safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2013</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
    <description>MACE was defined as a composite of Myocardial Infarction (MI), stroke, death, hospitalization for unstable angina, and hospitalization for Transient Ischemic Attack (TIA). Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Malignancies</measure>
    <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
    <description>Percentage of participants with one or more malignancy was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Serious Infections</measure>
    <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
    <description>Percentage of participants with one or more serious infections was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Gastrointestinal (GI) Perforations</measure>
    <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
    <description>Percentage of participants with one or more GI perforations was reported. GI perforation is a hole that develops through the entire wall of the stomach, small intestine, large bowel, or gallbladder.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hepatobiliary Abnormalities</measure>
    <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
    <description>Percentage of participants with hepatobiliary abnormalities was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Serious or Moderate/Severe Systemic Hypersensitivity Reactions, or Serum Sickness Adverse Events</measure>
    <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
    <description>Percentage of participants with serious or moderate/severe systemic hypersensitivity reactions, or serum sickness adverse events (AEs) was reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Toxicity Grade 4 Decrease in Neutrophils</measure>
    <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
    <description>Percentage of participants with toxicity grade 4 decrease in neutrophils was reported. As per National Cancer Institute's Common Terminology Criteria for Adverse Events, toxicity grade 4 was defined as decrease in neutrophils less than (&lt;) 500 per Cubic Millimeter (mm^3) or &lt; 0.5 * 10^9 per liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Toxicity Grade 4 Decrease in Platelets</measure>
    <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
    <description>Percentage of participants with toxicity grade 4 decrease in platelets was reported. As per National Cancer Institute's Common Terminology Criteria for Adverse Events, toxicity grade 4 was defined as decreased in platelets &lt;25000/mm^3 or &lt; 25.0 * 10^9 per liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ALT &gt;= 3*ULN, ALT &gt;= 5*ULN and ALT &gt;= 8*ULN</measure>
    <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
    <description>Percentage of participants with Alanine Aminotranserase (ALT) &gt;= 3*Upper Limit of Normal (ULN), ALT &gt;= 5*ULN or ALT &gt;= 8*ULN was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With AST &gt;= 3*ULN, AST &gt;= 5*ULN and AST &gt;= 8*ULN</measure>
    <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
    <description>Percentage of participants with Aspartate Aminotransferase (AST) &gt;= 3*ULN, AST &gt;= 5*ULN and AST &gt;= 8*ULN was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Either ALT &gt;= 3*ULN or AST &gt;= 3*ULN, and Total Bilirubin &gt;= 2*ULN</measure>
    <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
    <description>Percentage of participants with either ALT &gt;= 3*ULN or AST &gt;= 3*ULN and total bilirubin &gt;= 2*ULN was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal Total Cholesterol Value at Baseline and at Least 1 Abnormal Value Post-Baseline</measure>
    <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
    <description>Percentage of participants with normal total cholesterol value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal total cholesterol value was defined as total cholesterol value more than (&gt;) 200 milligrams per deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal Low-Density Lipoprotein (LDL) Value at Baseline and at Least 1 Abnormal Value Post-Baseline</measure>
    <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
    <description>Percentage of participants with normal LDL value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal LDL value was defined as LDL value &gt; 130 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal High-Density Lipoprotein (HDL) Value at Baseline and at Least 1 Abnormal Value Post-Baseline</measure>
    <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
    <description>Percentage of participants with normal HDL value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal HDL value was defined as HDL value &lt; 40 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal Triglyceride Value at Baseline and at Least 1 Abnormal Value Post-Baseline</measure>
    <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
    <description>Percentage of participants with normal triglyceride value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal triglyceride value was defined as triglyceride value &gt; 250 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response Through Week 260</measure>
    <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
    <description>ACR 50 response is greater than or equal to (&gt;=) 50 percent (%) improvement in both tender joint count (68) and swollen joint count (66) and &gt;= 50% improvement in 3 of following 5 assessments:Participant's assessment of pain using visual analog scale (VAS) (0-10 scale, 0=no pain and 10=worst possible pain),Participant's global assessment of disease activity by using VAS (scale ranges from 0 to 10, [0 = very well to 10 = very poor]), Physician's global assessment of disease activity using VAS (scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), Participant's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) (scale ranges from 0= no difficulty to 3= inability to perform a task in that area), and Serum C-reactive protein (CRP). Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Boolean-Based American College of Rheumatology (ACR) or European League Against Rheumatism (EULAR) Remission Through Week 260</measure>
    <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
    <description>Boolean based ACR/EULAR remission is achieved if all of the following 4 criteria at that visit are met: tender joint count (68 joints) &lt;=1; swollen joint count (66 joints) &lt;=1; CRP &lt;=1 milligram per deciliter (mg/dL); and patient's global assessment of disease activity on visual analog scale (VAS) &lt;=1 on a 0 (very well ) to 10 (extremely bad) scale. Higher scores indicates worst health condition. Participants were analyzed for efficacy according to the assigned treatment groups from the primary studies, regardless of the treatments they actually received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Activity Index Score 28 (CRP) Remission Through Week 260</measure>
    <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
    <description>The Disease Activity Index Score 28 (DAS28) based on C-Reactive Protein (CRP) is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission is defined as a DAS28 (CRP) value of less than (&lt;) 2.6 at any study visit. Participants were analyzed for efficacy according to the assigned treatment groups from the primary studies, regardless of the treatments they actually received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Disease Activity Index (CDAI) Score Through Week 260</measure>
    <time_frame>Baseline (Week 0 of primary studies), Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
    <description>The CDAI score is a derived score of 4 components: tender joints (28 joints), swollen joints (28 joints), patient's global assessment of disease activity, and physician's global assessments of disease activity. The total score ranges from 0 to 76 with a lower score indicating less disease activity. A negative change in CDAI score indicates an improvement in disease activity and a positive change in score indicates a worsening of disease activity. Participants were analyzed for efficacy according to the assigned treatment groups from the primary studies, regardless of the treatments they actually received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Simplified Disease Activity Index Based (SDAI-based) American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) Remission Through Week 260</measure>
    <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
    <description>Participant having SDAI-based ACR/EULAR remission at a visit if SDAI score is of &lt;= 3.3. SDAI derived by combining 5 disease assessments: tender joint (28), swollen joint (28) counts, participants global assessment of disease activity using VAS (scale ranges from 0 to 10 [0 =very well to 10 = very poor]), physicians global assessment of disease activity using VAS (scale ranges from 0 to 10 [0=no arthritis to 10=extremely active arthritis]) and CRP. 28 joints evaluated for swelling and tenderness are same set of 28 joints used in DAS28 includes shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of upper right and left extremities and knee joints of lower right and left extremities. Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score Through Week 260</measure>
    <time_frame>Baseline (Week 0 of primary studies), Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
    <description>The Health Assessment Questionnaire-Disability Index (HAQ-DI) score is an evaluation of the functional status for a participant. The 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty. Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Health Assessment Questionnaire-Disability Index (HAQ-DI) Response Through Week 260</measure>
    <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
    <description>HAQ-DI response was defined as change of less than -0.22 from baseline in HAQ-DI score. The HAQ-DI score is an evaluation of the functional status for a participant. The 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1820</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Sirukumab 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirukumab 50 mg / placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirukumab 100 mg</intervention_name>
    <description>Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.</description>
    <arm_group_label>Sirukumab 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirukumab 50 mg</intervention_name>
    <description>Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.</description>
    <arm_group_label>Sirukumab 50 mg / placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.</description>
    <arm_group_label>Sirukumab 50 mg / placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed participation in Studies CNTO136ARA3002 or CNTO136ARA3003

          -  Signed an informed consent form (ICF) indicating that they understand the purpose of
             and procedures required for the study and are willing to participate in the study

          -  Signed an informed consent form (ICF) for pharmacogenetics research (how a person's
             genes may affect a drug's effects) in order to participate in the optional
             pharmacogenetics component of this study. Refusal to give consent for this component
             does not exclude a participant from participation in this clinical study

        Exclusion Criteria:

          -  Withdraws consent and/or discontinues participation in study CNTO136ARA3002 or
             CNTO136ARA3003

          -  Is pregnant

          -  Has active diverticulitis

          -  Has any condition that, in the opinion of the investigator, would make participation
             not be in the best interest (eg, compromise the well-being) of the participant or that
             could prevent, limit, or confound the protocol-specified assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Covina</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Placentia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Upland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beckley</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel De Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancagua</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valdivia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vogelsang-Gommern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ayauta</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashihiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kato</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawagoe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kita-Gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishimuro-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sasebo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimonoseki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuke</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumida-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takaoka,Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokorozawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomishiro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tonami</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ureshino</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeonju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Namdong-Gu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alytus</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuching</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuernavaca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexicali</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morelia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis De Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ustron</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa N/a</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow N/a</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulyanovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niska Banja</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wigan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <results_first_submitted>April 12, 2019</results_first_submitted>
  <results_first_submitted_qc>April 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2019</results_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Sirukumab</keyword>
  <keyword>CNTO 136</keyword>
  <keyword>CNTO136ARA3002</keyword>
  <keyword>SIRROUND-D</keyword>
  <keyword>CNTO136ARA3003</keyword>
  <keyword>SIRROUND-T</keyword>
  <keyword>SIRROUND-LTE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01856309/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01856309/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants who completed participation in studies CNTO136ARA3002 (NCT01604343) and CNTO136ARA3003 (NCT01606761) and consented to participate in extension study were enrolled in this study.</recruitment_details>
      <pre_assignment_details>Data in the participant flow section is reported for treatment discontinuation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
          <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 milligram (mg) every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
        </group>
        <group group_id="P2">
          <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
          <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
        </group>
        <group group_id="P3">
          <title>Sirukumab 50 mg q4w</title>
          <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
        </group>
        <group group_id="P4">
          <title>Sirukumab 100 mg q2w</title>
          <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
                <participants group_id="P2" count="291"/>
                <participants group_id="P3" count="606"/>
                <participants group_id="P4" count="618"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants From Study CNTO136ARA3002</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="187"/>
                <participants group_id="P3" count="405"/>
                <participants group_id="P4" count="412"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants From Study CNTO136ARA3003</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="201"/>
                <participants group_id="P4" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Partcipants</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="605"/>
                <participants group_id="P4" count="618"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="288"/>
                <participants group_id="P3" count="595"/>
                <participants group_id="P4" count="609"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="225"/>
                <participants group_id="P3" count="447"/>
                <participants group_id="P4" count="469"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
          <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
        </group>
        <group group_id="B2">
          <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
          <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
        </group>
        <group group_id="B3">
          <title>Sirukumab 50 mg q4w</title>
          <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
        </group>
        <group group_id="B4">
          <title>Sirukumab 100 mg q2w</title>
          <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="305"/>
            <count group_id="B2" value="291"/>
            <count group_id="B3" value="606"/>
            <count group_id="B4" value="618"/>
            <count group_id="B5" value="1820"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="11.92"/>
                    <measurement group_id="B2" value="53.1" spread="11.75"/>
                    <measurement group_id="B3" value="53.1" spread="11.43"/>
                    <measurement group_id="B4" value="53.4" spread="11.29"/>
                    <measurement group_id="B5" value="53.4" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="479"/>
                    <measurement group_id="B4" value="503"/>
                    <measurement group_id="B5" value="1454"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="110"/>
                    <measurement group_id="B5" value="309"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="433"/>
                    <measurement group_id="B4" value="443"/>
                    <measurement group_id="B5" value="1318"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic Of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan, Province Of China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="149"/>
                    <measurement group_id="B5" value="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
        <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="26.4"/>
                    <measurement group_id="O4" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Major Adverse Cardiovascular Events (MACE)</title>
        <description>MACE was defined as a composite of Myocardial Infarction (MI), stroke, death, hospitalization for unstable angina, and hospitalization for Transient Ischemic Attack (TIA). Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion.</description>
        <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
        <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Major Adverse Cardiovascular Events (MACE)</title>
          <description>MACE was defined as a composite of Myocardial Infarction (MI), stroke, death, hospitalization for unstable angina, and hospitalization for Transient Ischemic Attack (TIA). Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion.</description>
          <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="2.3"/>
                    <measurement group_id="O4" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Malignancies</title>
        <description>Percentage of participants with one or more malignancy was reported.</description>
        <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
        <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Malignancies</title>
          <description>Percentage of participants with one or more malignancy was reported.</description>
          <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serious Infections</title>
        <description>Percentage of participants with one or more serious infections was reported.</description>
        <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
        <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Infections</title>
          <description>Percentage of participants with one or more serious infections was reported.</description>
          <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="12.0"/>
                    <measurement group_id="O3" value="10.4"/>
                    <measurement group_id="O4" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Gastrointestinal (GI) Perforations</title>
        <description>Percentage of participants with one or more GI perforations was reported. GI perforation is a hole that develops through the entire wall of the stomach, small intestine, large bowel, or gallbladder.</description>
        <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
        <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Gastrointestinal (GI) Perforations</title>
          <description>Percentage of participants with one or more GI perforations was reported. GI perforation is a hole that develops through the entire wall of the stomach, small intestine, large bowel, or gallbladder.</description>
          <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hepatobiliary Abnormalities</title>
        <description>Percentage of participants with hepatobiliary abnormalities was reported.</description>
        <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
        <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hepatobiliary Abnormalities</title>
          <description>Percentage of participants with hepatobiliary abnormalities was reported.</description>
          <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serious or Moderate/Severe Systemic Hypersensitivity Reactions, or Serum Sickness Adverse Events</title>
        <description>Percentage of participants with serious or moderate/severe systemic hypersensitivity reactions, or serum sickness adverse events (AEs) was reported.</description>
        <time_frame>From baseline of this LTE study up to 4.3 years</time_frame>
        <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious or Moderate/Severe Systemic Hypersensitivity Reactions, or Serum Sickness Adverse Events</title>
          <description>Percentage of participants with serious or moderate/severe systemic hypersensitivity reactions, or serum sickness adverse events (AEs) was reported.</description>
          <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Toxicity Grade 4 Decrease in Neutrophils</title>
        <description>Percentage of participants with toxicity grade 4 decrease in neutrophils was reported. As per National Cancer Institute's Common Terminology Criteria for Adverse Events, toxicity grade 4 was defined as decrease in neutrophils less than (&lt;) 500 per Cubic Millimeter (mm^3) or &lt; 0.5 * 10^9 per liter.</description>
        <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
        <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Toxicity Grade 4 Decrease in Neutrophils</title>
          <description>Percentage of participants with toxicity grade 4 decrease in neutrophils was reported. As per National Cancer Institute's Common Terminology Criteria for Adverse Events, toxicity grade 4 was defined as decrease in neutrophils less than (&lt;) 500 per Cubic Millimeter (mm^3) or &lt; 0.5 * 10^9 per liter.</description>
          <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Toxicity Grade 4 Decrease in Platelets</title>
        <description>Percentage of participants with toxicity grade 4 decrease in platelets was reported. As per National Cancer Institute's Common Terminology Criteria for Adverse Events, toxicity grade 4 was defined as decreased in platelets &lt;25000/mm^3 or &lt; 25.0 * 10^9 per liter.</description>
        <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
        <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Toxicity Grade 4 Decrease in Platelets</title>
          <description>Percentage of participants with toxicity grade 4 decrease in platelets was reported. As per National Cancer Institute's Common Terminology Criteria for Adverse Events, toxicity grade 4 was defined as decreased in platelets &lt;25000/mm^3 or &lt; 25.0 * 10^9 per liter.</description>
          <population>Population included all participants who were enrolled in this study. One participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ALT &gt;= 3*ULN, ALT &gt;= 5*ULN and ALT &gt;= 8*ULN</title>
        <description>Percentage of participants with Alanine Aminotranserase (ALT) &gt;= 3*Upper Limit of Normal (ULN), ALT &gt;= 5*ULN or ALT &gt;= 8*ULN was reported.</description>
        <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
        <population>Population included all participants who were enrolled in this study. 1 participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ALT &gt;= 3*ULN, ALT &gt;= 5*ULN and ALT &gt;= 8*ULN</title>
          <description>Percentage of participants with Alanine Aminotranserase (ALT) &gt;= 3*Upper Limit of Normal (ULN), ALT &gt;= 5*ULN or ALT &gt;= 8*ULN was reported.</description>
          <population>Population included all participants who were enrolled in this study. 1 participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT &gt;= 3 * ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="14.4"/>
                    <measurement group_id="O3" value="15.9"/>
                    <measurement group_id="O4" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt;= 5 * ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt;= 8 * ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With AST &gt;= 3*ULN, AST &gt;= 5*ULN and AST &gt;= 8*ULN</title>
        <description>Percentage of participants with Aspartate Aminotransferase (AST) &gt;= 3*ULN, AST &gt;= 5*ULN and AST &gt;= 8*ULN was reported.</description>
        <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
        <population>Population included all participants who were enrolled in this study. 1 participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With AST &gt;= 3*ULN, AST &gt;= 5*ULN and AST &gt;= 8*ULN</title>
          <description>Percentage of participants with Aspartate Aminotransferase (AST) &gt;= 3*ULN, AST &gt;= 5*ULN and AST &gt;= 8*ULN was reported.</description>
          <population>Population included all participants who were enrolled in this study. 1 participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST &gt;= 3 * ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="6.2"/>
                    <measurement group_id="O3" value="4.5"/>
                    <measurement group_id="O4" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt;= 5 * ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt;= 8 * ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Either ALT &gt;= 3*ULN or AST &gt;= 3*ULN, and Total Bilirubin &gt;= 2*ULN</title>
        <description>Percentage of participants with either ALT &gt;= 3*ULN or AST &gt;= 3*ULN and total bilirubin &gt;= 2*ULN was reported.</description>
        <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
        <population>Population included all participants who were enrolled in this study. 1 participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Either ALT &gt;= 3*ULN or AST &gt;= 3*ULN, and Total Bilirubin &gt;= 2*ULN</title>
          <description>Percentage of participants with either ALT &gt;= 3*ULN or AST &gt;= 3*ULN and total bilirubin &gt;= 2*ULN was reported.</description>
          <population>Population included all participants who were enrolled in this study. 1 participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="605"/>
                <count group_id="O4" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal Total Cholesterol Value at Baseline and at Least 1 Abnormal Value Post-Baseline</title>
        <description>Percentage of participants with normal total cholesterol value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal total cholesterol value was defined as total cholesterol value more than (&gt;) 200 milligrams per deciliter (mg/dL).</description>
        <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
        <population>Population included all participants who were enrolled in this study and had total cholesterol baseline value within normal range.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal Total Cholesterol Value at Baseline and at Least 1 Abnormal Value Post-Baseline</title>
          <description>Percentage of participants with normal total cholesterol value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal total cholesterol value was defined as total cholesterol value more than (&gt;) 200 milligrams per deciliter (mg/dL).</description>
          <population>Population included all participants who were enrolled in this study and had total cholesterol baseline value within normal range.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="354"/>
                <count group_id="O4" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="81.6"/>
                    <measurement group_id="O3" value="82.5"/>
                    <measurement group_id="O4" value="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal Low-Density Lipoprotein (LDL) Value at Baseline and at Least 1 Abnormal Value Post-Baseline</title>
        <description>Percentage of participants with normal LDL value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal LDL value was defined as LDL value &gt; 130 mg/dL.</description>
        <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
        <population>Population included all participants who were enrolled in this study and had LDL baseline value within normal range.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal Low-Density Lipoprotein (LDL) Value at Baseline and at Least 1 Abnormal Value Post-Baseline</title>
          <description>Percentage of participants with normal LDL value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal LDL value was defined as LDL value &gt; 130 mg/dL.</description>
          <population>Population included all participants who were enrolled in this study and had LDL baseline value within normal range.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="459"/>
                <count group_id="O4" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2"/>
                    <measurement group_id="O2" value="67.9"/>
                    <measurement group_id="O3" value="69.7"/>
                    <measurement group_id="O4" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal High-Density Lipoprotein (HDL) Value at Baseline and at Least 1 Abnormal Value Post-Baseline</title>
        <description>Percentage of participants with normal HDL value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal HDL value was defined as HDL value &lt; 40 mg/dL.</description>
        <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
        <population>Population included all participants who were enrolled in this study and had HDL baseline value within normal range.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal High-Density Lipoprotein (HDL) Value at Baseline and at Least 1 Abnormal Value Post-Baseline</title>
          <description>Percentage of participants with normal HDL value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal HDL value was defined as HDL value &lt; 40 mg/dL.</description>
          <population>Population included all participants who were enrolled in this study and had HDL baseline value within normal range.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="533"/>
                <count group_id="O4" value="569"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="16.1"/>
                    <measurement group_id="O4" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal Triglyceride Value at Baseline and at Least 1 Abnormal Value Post-Baseline</title>
        <description>Percentage of participants with normal triglyceride value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal triglyceride value was defined as triglyceride value &gt; 250 mg/dL.</description>
        <time_frame>From baseline of primary studies through end of this LTE study (Approximately 5.3 years)</time_frame>
        <population>Population included all participants who were enrolled in this study and had triglyceride baseline value within normal range.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal Triglyceride Value at Baseline and at Least 1 Abnormal Value Post-Baseline</title>
          <description>Percentage of participants with normal triglyceride value at baseline and at least 1 abnormal value post-baseline was reported. Abnormal triglyceride value was defined as triglyceride value &gt; 250 mg/dL.</description>
          <population>Population included all participants who were enrolled in this study and had triglyceride baseline value within normal range.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="554"/>
                <count group_id="O4" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="35.1"/>
                    <measurement group_id="O3" value="36.1"/>
                    <measurement group_id="O4" value="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response Through Week 260</title>
        <description>ACR 50 response is greater than or equal to (&gt;=) 50 percent (%) improvement in both tender joint count (68) and swollen joint count (66) and &gt;= 50% improvement in 3 of following 5 assessments:Participant's assessment of pain using visual analog scale (VAS) (0-10 scale, 0=no pain and 10=worst possible pain),Participant's global assessment of disease activity by using VAS (scale ranges from 0 to 10, [0 = very well to 10 = very poor]), Physician's global assessment of disease activity using VAS (scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), Participant's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) (scale ranges from 0= no difficulty to 3= inability to perform a task in that area), and Serum C-reactive protein (CRP). Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
        <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
        <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response Through Week 260</title>
          <description>ACR 50 response is greater than or equal to (&gt;=) 50 percent (%) improvement in both tender joint count (68) and swollen joint count (66) and &gt;= 50% improvement in 3 of following 5 assessments:Participant's assessment of pain using visual analog scale (VAS) (0-10 scale, 0=no pain and 10=worst possible pain),Participant's global assessment of disease activity by using VAS (scale ranges from 0 to 10, [0 = very well to 10 = very poor]), Physician's global assessment of disease activity using VAS (scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), Participant's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) (scale ranges from 0= no difficulty to 3= inability to perform a task in that area), and Serum C-reactive protein (CRP). Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
          <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="604"/>
                    <count group_id="O4" value="615"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="9.1"/>
                    <measurement group_id="O4" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="511"/>
                    <count group_id="O4" value="527"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="16.2"/>
                    <measurement group_id="O4" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="21.4"/>
                    <measurement group_id="O4" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="27.7"/>
                    <measurement group_id="O4" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="31.8"/>
                    <measurement group_id="O4" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="33.7"/>
                    <measurement group_id="O4" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="36.9"/>
                    <measurement group_id="O4" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="606"/>
                    <count group_id="O4" value="615"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="10.4"/>
                    <measurement group_id="O3" value="35.1"/>
                    <measurement group_id="O4" value="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="30.2"/>
                    <measurement group_id="O3" value="40.9"/>
                    <measurement group_id="O4" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2"/>
                    <measurement group_id="O2" value="33.9"/>
                    <measurement group_id="O3" value="42.3"/>
                    <measurement group_id="O4" value="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="595"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3"/>
                    <measurement group_id="O2" value="34.7"/>
                    <measurement group_id="O3" value="42.0"/>
                    <measurement group_id="O4" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="598"/>
                    <count group_id="O4" value="609"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1"/>
                    <measurement group_id="O2" value="33.5"/>
                    <measurement group_id="O3" value="43.3"/>
                    <measurement group_id="O4" value="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="44.6"/>
                    <measurement group_id="O4" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="182"/>
                    <count group_id="O3" value="605"/>
                    <count group_id="O4" value="617"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="43.0"/>
                    <measurement group_id="O4" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="185"/>
                    <count group_id="O3" value="401"/>
                    <count group_id="O4" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6"/>
                    <measurement group_id="O2" value="49.7"/>
                    <measurement group_id="O3" value="52.4"/>
                    <measurement group_id="O4" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="178"/>
                    <count group_id="O4" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9"/>
                    <measurement group_id="O2" value="26.4"/>
                    <measurement group_id="O3" value="38.2"/>
                    <measurement group_id="O4" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="571"/>
                    <count group_id="O4" value="575"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="46.1"/>
                    <measurement group_id="O3" value="50.3"/>
                    <measurement group_id="O4" value="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="43.8"/>
                    <measurement group_id="O3" value="42.7"/>
                    <measurement group_id="O4" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="356"/>
                    <count group_id="O4" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="46.7"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="242"/>
                    <count group_id="O2" value="227"/>
                    <count group_id="O3" value="499"/>
                    <count group_id="O4" value="506"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3"/>
                    <measurement group_id="O2" value="56.4"/>
                    <measurement group_id="O3" value="50.3"/>
                    <measurement group_id="O4" value="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="175"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="54.9"/>
                    <measurement group_id="O3" value="54.6"/>
                    <measurement group_id="O4" value="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9"/>
                    <measurement group_id="O2" value="50.5"/>
                    <measurement group_id="O3" value="50.8"/>
                    <measurement group_id="O4" value="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 232</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="51.5"/>
                    <measurement group_id="O4" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="60.0"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Boolean-Based American College of Rheumatology (ACR) or European League Against Rheumatism (EULAR) Remission Through Week 260</title>
        <description>Boolean based ACR/EULAR remission is achieved if all of the following 4 criteria at that visit are met: tender joint count (68 joints) &lt;=1; swollen joint count (66 joints) &lt;=1; CRP &lt;=1 milligram per deciliter (mg/dL); and patient's global assessment of disease activity on visual analog scale (VAS) &lt;=1 on a 0 (very well ) to 10 (extremely bad) scale. Higher scores indicates worst health condition. Participants were analyzed for efficacy according to the assigned treatment groups from the primary studies, regardless of the treatments they actually received.</description>
        <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
        <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Boolean-Based American College of Rheumatology (ACR) or European League Against Rheumatism (EULAR) Remission Through Week 260</title>
          <description>Boolean based ACR/EULAR remission is achieved if all of the following 4 criteria at that visit are met: tender joint count (68 joints) &lt;=1; swollen joint count (66 joints) &lt;=1; CRP &lt;=1 milligram per deciliter (mg/dL); and patient's global assessment of disease activity on visual analog scale (VAS) &lt;=1 on a 0 (very well ) to 10 (extremely bad) scale. Higher scores indicates worst health condition. Participants were analyzed for efficacy according to the assigned treatment groups from the primary studies, regardless of the treatments they actually received.</description>
          <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="604"/>
                    <count group_id="O4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="511"/>
                    <count group_id="O4" value="527"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.8"/>
                    <measurement group_id="O4" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.2"/>
                    <measurement group_id="O4" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.3"/>
                    <measurement group_id="O4" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="604"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4.5"/>
                    <measurement group_id="O4" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="606"/>
                    <count group_id="O4" value="615"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="5.3"/>
                    <measurement group_id="O4" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="6.0"/>
                    <measurement group_id="O4" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="7.8"/>
                    <measurement group_id="O4" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="596"/>
                    <count group_id="O4" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="7.2"/>
                    <measurement group_id="O4" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="180"/>
                    <count group_id="O3" value="598"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="7.4"/>
                    <measurement group_id="O4" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="609"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="9.8"/>
                    <measurement group_id="O4" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="181"/>
                    <count group_id="O3" value="604"/>
                    <count group_id="O4" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="6.6"/>
                    <measurement group_id="O3" value="9.3"/>
                    <measurement group_id="O4" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="10.7"/>
                    <measurement group_id="O4" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="180"/>
                    <count group_id="O4" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="7.8"/>
                    <measurement group_id="O4" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="270"/>
                    <count group_id="O3" value="573"/>
                    <count group_id="O4" value="578"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="12.6"/>
                    <measurement group_id="O4" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="8.1"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="168"/>
                    <count group_id="O3" value="360"/>
                    <count group_id="O4" value="373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                    <measurement group_id="O2" value="11.3"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="229"/>
                    <count group_id="O3" value="503"/>
                    <count group_id="O4" value="508"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="10.9"/>
                    <measurement group_id="O4" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="177"/>
                    <count group_id="O3" value="386"/>
                    <count group_id="O4" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="14.2"/>
                    <measurement group_id="O4" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="201"/>
                    <count group_id="O4" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="13.7"/>
                    <measurement group_id="O3" value="11.4"/>
                    <measurement group_id="O4" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 232</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="18.2"/>
                    <measurement group_id="O4" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="18.2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Activity Index Score 28 (CRP) Remission Through Week 260</title>
        <description>The Disease Activity Index Score 28 (DAS28) based on C-Reactive Protein (CRP) is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission is defined as a DAS28 (CRP) value of less than (&lt;) 2.6 at any study visit. Participants were analyzed for efficacy according to the assigned treatment groups from the primary studies, regardless of the treatments they actually received.</description>
        <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
        <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Activity Index Score 28 (CRP) Remission Through Week 260</title>
          <description>The Disease Activity Index Score 28 (DAS28) based on C-Reactive Protein (CRP) is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission is defined as a DAS28 (CRP) value of less than (&lt;) 2.6 at any study visit. Participants were analyzed for efficacy according to the assigned treatment groups from the primary studies, regardless of the treatments they actually received.</description>
          <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="609"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="599"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="7.5"/>
                    <measurement group_id="O4" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="502"/>
                    <count group_id="O4" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="10.2"/>
                    <measurement group_id="O4" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="15.0"/>
                    <measurement group_id="O4" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="598"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="20.4"/>
                    <measurement group_id="O4" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="23.8"/>
                    <measurement group_id="O4" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="589"/>
                    <count group_id="O4" value="606"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="25.6"/>
                    <measurement group_id="O4" value="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="605"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="29.8"/>
                    <measurement group_id="O4" value="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="7.5"/>
                    <measurement group_id="O3" value="30.8"/>
                    <measurement group_id="O4" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="595"/>
                    <count group_id="O4" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                    <measurement group_id="O2" value="20.8"/>
                    <measurement group_id="O3" value="33.8"/>
                    <measurement group_id="O4" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="597"/>
                    <count group_id="O4" value="609"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="35.3"/>
                    <measurement group_id="O4" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="596"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="30.5"/>
                    <measurement group_id="O3" value="35.1"/>
                    <measurement group_id="O4" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="172"/>
                    <count group_id="O3" value="594"/>
                    <count group_id="O4" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="32.0"/>
                    <measurement group_id="O3" value="34.5"/>
                    <measurement group_id="O4" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="595"/>
                    <count group_id="O4" value="607"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                    <measurement group_id="O2" value="30.9"/>
                    <measurement group_id="O3" value="36.0"/>
                    <measurement group_id="O4" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="592"/>
                    <count group_id="O4" value="605"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="38.7"/>
                    <measurement group_id="O4" value="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="181"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7"/>
                    <measurement group_id="O2" value="32.6"/>
                    <measurement group_id="O3" value="38.8"/>
                    <measurement group_id="O4" value="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="399"/>
                    <count group_id="O4" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6"/>
                    <measurement group_id="O2" value="44.3"/>
                    <measurement group_id="O3" value="47.6"/>
                    <measurement group_id="O4" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="175"/>
                    <count group_id="O4" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9"/>
                    <measurement group_id="O2" value="39.3"/>
                    <measurement group_id="O3" value="38.3"/>
                    <measurement group_id="O4" value="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="279"/>
                    <count group_id="O2" value="266"/>
                    <count group_id="O3" value="571"/>
                    <count group_id="O4" value="573"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                    <measurement group_id="O2" value="47.4"/>
                    <measurement group_id="O3" value="42.6"/>
                    <measurement group_id="O4" value="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="156"/>
                    <count group_id="O4" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="43.1"/>
                    <measurement group_id="O3" value="45.5"/>
                    <measurement group_id="O4" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="350"/>
                    <count group_id="O4" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4"/>
                    <measurement group_id="O2" value="47.3"/>
                    <measurement group_id="O3" value="48.0"/>
                    <measurement group_id="O4" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="233"/>
                    <count group_id="O3" value="486"/>
                    <count group_id="O4" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0"/>
                    <measurement group_id="O2" value="47.1"/>
                    <measurement group_id="O3" value="46.5"/>
                    <measurement group_id="O4" value="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="376"/>
                    <count group_id="O4" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="48.8"/>
                    <measurement group_id="O3" value="50.5"/>
                    <measurement group_id="O4" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0"/>
                    <measurement group_id="O2" value="54.8"/>
                    <measurement group_id="O3" value="54.3"/>
                    <measurement group_id="O4" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 232</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3"/>
                    <measurement group_id="O2" value="52.0"/>
                    <measurement group_id="O3" value="57.1"/>
                    <measurement group_id="O4" value="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Disease Activity Index (CDAI) Score Through Week 260</title>
        <description>The CDAI score is a derived score of 4 components: tender joints (28 joints), swollen joints (28 joints), patient's global assessment of disease activity, and physician's global assessments of disease activity. The total score ranges from 0 to 76 with a lower score indicating less disease activity. A negative change in CDAI score indicates an improvement in disease activity and a positive change in score indicates a worsening of disease activity. Participants were analyzed for efficacy according to the assigned treatment groups from the primary studies, regardless of the treatments they actually received.</description>
        <time_frame>Baseline (Week 0 of primary studies), Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
        <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Disease Activity Index (CDAI) Score Through Week 260</title>
          <description>The CDAI score is a derived score of 4 components: tender joints (28 joints), swollen joints (28 joints), patient's global assessment of disease activity, and physician's global assessments of disease activity. The total score ranges from 0 to 76 with a lower score indicating less disease activity. A negative change in CDAI score indicates an improvement in disease activity and a positive change in score indicates a worsening of disease activity. Participants were analyzed for efficacy according to the assigned treatment groups from the primary studies, regardless of the treatments they actually received.</description>
          <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at specified time point.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-6.54" spread="9.464"/>
                    <measurement group_id="O4" value="-6.10" spread="9.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="598"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-11.09" spread="11.257"/>
                    <measurement group_id="O4" value="-10.73" spread="11.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="510"/>
                    <count group_id="O4" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-13.79" spread="12.198"/>
                    <measurement group_id="O4" value="-14.05" spread="11.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-15.56" spread="12.736"/>
                    <measurement group_id="O4" value="-15.74" spread="12.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-17.79" spread="13.955"/>
                    <measurement group_id="O4" value="-17.89" spread="13.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-18.50" spread="13.956"/>
                    <measurement group_id="O4" value="-18.65" spread="13.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="599"/>
                    <count group_id="O4" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-18.93" spread="14.459"/>
                    <measurement group_id="O4" value="-18.40" spread="13.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.19" spread="12.051"/>
                    <measurement group_id="O2" value="-7.01" spread="11.666"/>
                    <measurement group_id="O3" value="-20.72" spread="14.077"/>
                    <measurement group_id="O4" value="-19.96" spread="13.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="605"/>
                    <count group_id="O4" value="615"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.08" spread="11.697"/>
                    <measurement group_id="O2" value="-12.78" spread="11.654"/>
                    <measurement group_id="O3" value="-21.20" spread="13.625"/>
                    <measurement group_id="O4" value="-21.06" spread="13.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="172"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.69" spread="13.518"/>
                    <measurement group_id="O2" value="-19.58" spread="12.578"/>
                    <measurement group_id="O3" value="-21.85" spread="14.000"/>
                    <measurement group_id="O4" value="-21.33" spread="13.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.36" spread="14.238"/>
                    <measurement group_id="O2" value="-20.69" spread="12.754"/>
                    <measurement group_id="O3" value="-22.37" spread="13.935"/>
                    <measurement group_id="O4" value="-22.17" spread="13.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.49" spread="12.343"/>
                    <measurement group_id="O2" value="-22.53" spread="12.609"/>
                    <measurement group_id="O3" value="-22.64" spread="13.750"/>
                    <measurement group_id="O4" value="-22.79" spread="13.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="593"/>
                    <count group_id="O4" value="609"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.67" spread="13.374"/>
                    <measurement group_id="O2" value="-22.36" spread="13.208"/>
                    <measurement group_id="O3" value="-23.09" spread="13.890"/>
                    <measurement group_id="O4" value="-22.49" spread="14.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="596"/>
                    <count group_id="O4" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.80" spread="14.390"/>
                    <measurement group_id="O2" value="-22.31" spread="13.062"/>
                    <measurement group_id="O3" value="-23.19" spread="14.214"/>
                    <measurement group_id="O4" value="23.04" spread="13.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="599"/>
                    <count group_id="O4" value="606"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.74" spread="13.685"/>
                    <measurement group_id="O2" value="-22.56" spread="13.229"/>
                    <measurement group_id="O3" value="-23.22" spread="14.281"/>
                    <measurement group_id="O4" value="-23.20" spread="13.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="617"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.09" spread="13.629"/>
                    <measurement group_id="O2" value="-23.17" spread="13.280"/>
                    <measurement group_id="O3" value="-24.05" spread="13.930"/>
                    <measurement group_id="O4" value="-23.61" spread="13.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="185"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.49" spread="12.763"/>
                    <measurement group_id="O2" value="-25.91" spread="13.537"/>
                    <measurement group_id="O3" value="-25.98" spread="14.077"/>
                    <measurement group_id="O4" value="-24.83" spread="12.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="174"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.31" spread="14.840"/>
                    <measurement group_id="O2" value="-22.67" spread="12.546"/>
                    <measurement group_id="O3" value="-23.27" spread="15.372"/>
                    <measurement group_id="O4" value="-23.70" spread="14.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="569"/>
                    <count group_id="O4" value="573"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.85" spread="13.261"/>
                    <measurement group_id="O2" value="-26.08" spread="12.872"/>
                    <measurement group_id="O3" value="-25.75" spread="13.931"/>
                    <measurement group_id="O4" value="-25.60" spread="13.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="154"/>
                    <count group_id="O4" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.55" spread="13.797"/>
                    <measurement group_id="O2" value="-25.12" spread="12.102"/>
                    <measurement group_id="O3" value="-25.06" spread="15.496"/>
                    <measurement group_id="O4" value="-26.14" spread="14.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="347"/>
                    <count group_id="O4" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.24" spread="12.671"/>
                    <measurement group_id="O2" value="-26.62" spread="13.994"/>
                    <measurement group_id="O3" value="-26.06" spread="13.661"/>
                    <measurement group_id="O4" value="-24.61" spread="13.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="238"/>
                    <count group_id="O2" value="225"/>
                    <count group_id="O3" value="489"/>
                    <count group_id="O4" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.53" spread="14.998"/>
                    <measurement group_id="O2" value="-26.85" spread="13.999"/>
                    <measurement group_id="O3" value="-25.59" spread="14.641"/>
                    <measurement group_id="O4" value="-25.60" spread="13.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="168"/>
                    <count group_id="O3" value="375"/>
                    <count group_id="O4" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.21" spread="14.370"/>
                    <measurement group_id="O2" value="-27.07" spread="13.969"/>
                    <measurement group_id="O3" value="-26.95" spread="13.671"/>
                    <measurement group_id="O4" value="-25.88" spread="13.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.54" spread="12.054"/>
                    <measurement group_id="O2" value="-27.06" spread="15.579"/>
                    <measurement group_id="O3" value="-27.01" spread="12.968"/>
                    <measurement group_id="O4" value="-27.12" spread="13.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 232</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.61" spread="13.420"/>
                    <measurement group_id="O2" value="-26.25" spread="17.509"/>
                    <measurement group_id="O3" value="-26.06" spread="16.858"/>
                    <measurement group_id="O4" value="-27.23" spread="14.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.70" spread="4.776"/>
                    <measurement group_id="O2" value="-26.60" spread="20.789"/>
                    <measurement group_id="O3" value="-20.73" spread="11.983"/>
                    <measurement group_id="O4" value="-19.03" spread="18.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Simplified Disease Activity Index Based (SDAI-based) American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) Remission Through Week 260</title>
        <description>Participant having SDAI-based ACR/EULAR remission at a visit if SDAI score is of &lt;= 3.3. SDAI derived by combining 5 disease assessments: tender joint (28), swollen joint (28) counts, participants global assessment of disease activity using VAS (scale ranges from 0 to 10 [0 =very well to 10 = very poor]), physicians global assessment of disease activity using VAS (scale ranges from 0 to 10 [0=no arthritis to 10=extremely active arthritis]) and CRP. 28 joints evaluated for swelling and tenderness are same set of 28 joints used in DAS28 includes shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of upper right and left extremities and knee joints of lower right and left extremities. Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
        <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
        <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Simplified Disease Activity Index Based (SDAI-based) American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) Remission Through Week 260</title>
          <description>Participant having SDAI-based ACR/EULAR remission at a visit if SDAI score is of &lt;= 3.3. SDAI derived by combining 5 disease assessments: tender joint (28), swollen joint (28) counts, participants global assessment of disease activity using VAS (scale ranges from 0 to 10 [0 =very well to 10 = very poor]), physicians global assessment of disease activity using VAS (scale ranges from 0 to 10 [0=no arthritis to 10=extremely active arthritis]) and CRP. 28 joints evaluated for swelling and tenderness are same set of 28 joints used in DAS28 includes shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of upper right and left extremities and knee joints of lower right and left extremities. Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
          <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="609"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="596"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.8"/>
                    <measurement group_id="O4" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="502"/>
                    <count group_id="O4" value="522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.8"/>
                    <measurement group_id="O4" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="598"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.5"/>
                    <measurement group_id="O4" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.2"/>
                    <measurement group_id="O4" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="587"/>
                    <count group_id="O4" value="606"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="7.5"/>
                    <measurement group_id="O4" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8.0"/>
                    <measurement group_id="O4" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="9.8"/>
                    <measurement group_id="O4" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="172"/>
                    <count group_id="O3" value="595"/>
                    <count group_id="O4" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="10.4"/>
                    <measurement group_id="O4" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="596"/>
                    <count group_id="O4" value="607"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="9.9"/>
                    <measurement group_id="O4" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="596"/>
                    <count group_id="O4" value="609"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="7.5"/>
                    <measurement group_id="O3" value="11.7"/>
                    <measurement group_id="O4" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="172"/>
                    <count group_id="O3" value="592"/>
                    <count group_id="O4" value="605"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="11.0"/>
                    <measurement group_id="O3" value="13.7"/>
                    <measurement group_id="O4" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="176"/>
                    <count group_id="O3" value="595"/>
                    <count group_id="O4" value="605"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="10.2"/>
                    <measurement group_id="O3" value="11.8"/>
                    <measurement group_id="O4" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="591"/>
                    <count group_id="O4" value="603"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="12.3"/>
                    <measurement group_id="O3" value="14.9"/>
                    <measurement group_id="O4" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="181"/>
                    <count group_id="O3" value="600"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="905"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="15.0"/>
                    <measurement group_id="O4" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="399"/>
                    <count group_id="O4" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="13.7"/>
                    <measurement group_id="O3" value="16.8"/>
                    <measurement group_id="O4" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="174"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="12.6"/>
                    <measurement group_id="O4" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="279"/>
                    <count group_id="O2" value="264"/>
                    <count group_id="O3" value="568"/>
                    <count group_id="O4" value="571"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="17.8"/>
                    <measurement group_id="O4" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="15.3"/>
                    <measurement group_id="O3" value="16.1"/>
                    <measurement group_id="O4" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="347"/>
                    <count group_id="O4" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="20.5"/>
                    <measurement group_id="O4" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="223"/>
                    <count group_id="O3" value="483"/>
                    <count group_id="O4" value="499"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="17.8"/>
                    <measurement group_id="O4" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="374"/>
                    <count group_id="O4" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="22.5"/>
                    <measurement group_id="O4" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="20.7"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 232</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.39"/>
                    <measurement group_id="O2" value="20.2"/>
                    <measurement group_id="O3" value="27.3"/>
                    <measurement group_id="O4" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score Through Week 260</title>
        <description>The Health Assessment Questionnaire-Disability Index (HAQ-DI) score is an evaluation of the functional status for a participant. The 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty. Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
        <time_frame>Baseline (Week 0 of primary studies), Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
        <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after the escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies number of participants analyzed at specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score Through Week 260</title>
          <description>The Health Assessment Questionnaire-Disability Index (HAQ-DI) score is an evaluation of the functional status for a participant. The 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty. Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
          <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after the escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies number of participants analyzed at specified time point.</population>
          <units>Units on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-0.1136" spread="0.3455"/>
                    <measurement group_id="O4" value="-0.1230" spread="0.3741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-0.2307" spread="0.4173"/>
                    <measurement group_id="O4" value="-0.2417" spread="0.4034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="511"/>
                    <count group_id="O4" value="526"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-0.3112" spread="0.4944"/>
                    <measurement group_id="O4" value="-0.3683" spread="0.4823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-0.3499" spread="0.5077"/>
                    <measurement group_id="O4" value="-0.3914" spread="0.5022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-0.3866" spread="0.5421"/>
                    <measurement group_id="O4" value="-0.4121" spread="0.5270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="606"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-0.3991" spread="0.5611"/>
                    <measurement group_id="O4" value="-0.4414" spread="0.5430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-0.4365" spread="0.5476"/>
                    <measurement group_id="O4" value="-0.4621" spread="0.5325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1363" spread="0.4947"/>
                    <measurement group_id="O2" value="-0.2005" spread="0.4987"/>
                    <measurement group_id="O3" value="-0.4425" spread="0.5826"/>
                    <measurement group_id="O4" value="-0.4920" spread="0.5582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="605"/>
                    <count group_id="O4" value="615"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3192" spread="0.5279"/>
                    <measurement group_id="O2" value="-0.3267" spread="0.4739"/>
                    <measurement group_id="O3" value="-0.4506" spread="0.5665"/>
                    <measurement group_id="O4" value="-0.4876" spread="0.5622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3722" spread="0.5683"/>
                    <measurement group_id="O2" value="-0.3836" spread="0.4741"/>
                    <measurement group_id="O3" value="-0.4736" spread="0.5696"/>
                    <measurement group_id="O4" value="-0.4912" spread="0.5626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3847" spread="0.5651"/>
                    <measurement group_id="O2" value="-0.4015" spread="0.5532"/>
                    <measurement group_id="O3" value="-0.4769" spread="0.5880"/>
                    <measurement group_id="O4" value="-0.5307" spread="0.5740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3862" spread="0.5474"/>
                    <measurement group_id="O2" value="-0.4339" spread="0.5432"/>
                    <measurement group_id="O3" value="-0.4850" spread="0.5764"/>
                    <measurement group_id="O4" value="-0.5176" spread="0.5688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="593"/>
                    <count group_id="O4" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4138" spread="0.5778"/>
                    <measurement group_id="O2" value="-0.4509" spread="0.4988"/>
                    <measurement group_id="O3" value="-0.4850" spread="0.5894"/>
                    <measurement group_id="O4" value="-0.5039" spread="0.5735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="181"/>
                    <count group_id="O3" value="597"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4231" spread="0.5809"/>
                    <measurement group_id="O2" value="-0.4461" spread="0.5206"/>
                    <measurement group_id="O3" value="-0.4906" spread="0.6088"/>
                    <measurement group_id="O4" value="-0.5297" spread="0.5777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="609"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4392" spread="0.5911"/>
                    <measurement group_id="O2" value="-0.4567" spread="0.5254"/>
                    <measurement group_id="O3" value="-0.4890" spread="0.6242"/>
                    <measurement group_id="O4" value="-0.5470" spread="0.5942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="182"/>
                    <count group_id="O3" value="604"/>
                    <count group_id="O4" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4228" spread="0.5752"/>
                    <measurement group_id="O2" value="-0.4609" spread="0.5455"/>
                    <measurement group_id="O3" value="-0.4946" spread="0.6021"/>
                    <measurement group_id="O4" value="-0.5374" spread="0.5881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="185"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5816" spread="0.6313"/>
                    <measurement group_id="O2" value="-0.5351" spread="0.5605"/>
                    <measurement group_id="O3" value="-0.5628" spread="0.6089"/>
                    <measurement group_id="O4" value="-0.6128" spread="0.5992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="179"/>
                    <count group_id="O4" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2074" spread="0.5333"/>
                    <measurement group_id="O2" value="-0.3980" spread="0.5579"/>
                    <measurement group_id="O3" value="-0.3834" spread="0.5685"/>
                    <measurement group_id="O4" value="-0.4211" spread="0.5626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="269"/>
                    <count group_id="O3" value="573"/>
                    <count group_id="O4" value="579"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4778" spread="0.6569"/>
                    <measurement group_id="O2" value="-0.5107" spread="0.5958"/>
                    <measurement group_id="O3" value="-0.5153" spread="0.6094"/>
                    <measurement group_id="O4" value="-0.5579" spread="0.5913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2664" spread="0.5963"/>
                    <measurement group_id="O2" value="-0.4476" spread="0.5263"/>
                    <measurement group_id="O3" value="-0.3615" spread="0.6227"/>
                    <measurement group_id="O4" value="-0.4506" spread="0.5527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="362"/>
                    <count group_id="O4" value="375"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4831" spread="0.6979"/>
                    <measurement group_id="O2" value="-0.4815" spread="0.6656"/>
                    <measurement group_id="O3" value="-0.5045" spread="0.6542"/>
                    <measurement group_id="O4" value="-0.5310" spread="0.6240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="503"/>
                    <count group_id="O4" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4614" spread="0.6610"/>
                    <measurement group_id="O2" value="-0.4984" spread="0.6520"/>
                    <measurement group_id="O3" value="-0.4719" spread="0.6604"/>
                    <measurement group_id="O4" value="-0.4998" spread="0.6109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="384"/>
                    <count group_id="O4" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4505" spread="0.7024"/>
                    <measurement group_id="O2" value="-0.4957" spread="0.5969"/>
                    <measurement group_id="O3" value="-0.5072" spread="0.6492"/>
                    <measurement group_id="O4" value="-0.5258" spread="0.6167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="201"/>
                    <count group_id="O4" value="217"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4622" spread="0.6898"/>
                    <measurement group_id="O2" value="-0.4973" spread="0.6032"/>
                    <measurement group_id="O3" value="-0.5031" spread="0.6701"/>
                    <measurement group_id="O4" value="-0.5588" spread="0.6023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 232</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4191" spread="0.7410"/>
                    <measurement group_id="O2" value="-0.4655" spread="0.6477"/>
                    <measurement group_id="O3" value="-0.5877" spread="0.8312"/>
                    <measurement group_id="O4" value="-0.6069" spread="0.6262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5417" spread="0.8323"/>
                    <measurement group_id="O2" value="-0.3750" spread="1.0607"/>
                    <measurement group_id="O3" value="-0.2083" spread="0.6702"/>
                    <measurement group_id="O4" value="-0.5000" spread="0.4507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Health Assessment Questionnaire-Disability Index (HAQ-DI) Response Through Week 260</title>
        <description>HAQ-DI response was defined as change of less than -0.22 from baseline in HAQ-DI score. The HAQ-DI score is an evaluation of the functional status for a participant. The 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
        <time_frame>Week 2, 4, 6, 8, 12, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, 76, 80, 104, 128, 132, 156, 180, 208, 232 and 260</time_frame>
        <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
            <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O3">
            <title>Sirukumab 50 mg q4w</title>
            <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
          <group group_id="O4">
            <title>Sirukumab 100 mg q2w</title>
            <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Health Assessment Questionnaire-Disability Index (HAQ-DI) Response Through Week 260</title>
          <description>HAQ-DI response was defined as change of less than -0.22 from baseline in HAQ-DI score. The HAQ-DI score is an evaluation of the functional status for a participant. The 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Participants were analyzed for efficacy according to assigned treatment groups from the primary studies, regardless of treatments actually received.</description>
          <population>Population included all participants who were enrolled in this study. For &quot;Placebo to 50mg&quot; and &quot;Placebo to 100mg&quot; groups, only efficacy data collected after escape or CO (after Week 18) to sirukumab was planned to be reported, with exception of baseline data. Here 'n' signifies the number of participants analyzed at the specified time point.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="606"/>
                <count group_id="O4" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="603"/>
                    <count group_id="O4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="36.3"/>
                    <measurement group_id="O4" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="616"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="48.3"/>
                    <measurement group_id="O4" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="511"/>
                    <count group_id="O4" value="526"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="56.4"/>
                    <measurement group_id="O4" value="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="58.0"/>
                    <measurement group_id="O4" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="60.4"/>
                    <measurement group_id="O4" value="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="62.0"/>
                    <measurement group_id="O4" value="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="63.0"/>
                    <measurement group_id="O4" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="45.3"/>
                    <measurement group_id="O3" value="64.0"/>
                    <measurement group_id="O4" value="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="605"/>
                    <count group_id="O4" value="615"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                    <measurement group_id="O2" value="54.7"/>
                    <measurement group_id="O3" value="64.3"/>
                    <measurement group_id="O4" value="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="61.5"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="59.4"/>
                    <measurement group_id="O3" value="65.2"/>
                    <measurement group_id="O4" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="64.9"/>
                    <measurement group_id="O3" value="67.1"/>
                    <measurement group_id="O4" value="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="593"/>
                    <count group_id="O4" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0"/>
                    <measurement group_id="O2" value="67.1"/>
                    <measurement group_id="O3" value="65.4"/>
                    <measurement group_id="O4" value="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="181"/>
                    <count group_id="O3" value="597"/>
                    <count group_id="O4" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6"/>
                    <measurement group_id="O2" value="65.2"/>
                    <measurement group_id="O3" value="65.8"/>
                    <measurement group_id="O4" value="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="179"/>
                    <count group_id="O3" value="601"/>
                    <count group_id="O4" value="609"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="65.9"/>
                    <measurement group_id="O3" value="65.6"/>
                    <measurement group_id="O4" value="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="182"/>
                    <count group_id="O3" value="604"/>
                    <count group_id="O4" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="65.9"/>
                    <measurement group_id="O3" value="65.6"/>
                    <measurement group_id="O4" value="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="185"/>
                    <count group_id="O3" value="598"/>
                    <count group_id="O4" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4"/>
                    <measurement group_id="O2" value="69.2"/>
                    <measurement group_id="O3" value="68.4"/>
                    <measurement group_id="O4" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="179"/>
                    <count group_id="O4" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                    <measurement group_id="O2" value="58.6"/>
                    <measurement group_id="O3" value="58.1"/>
                    <measurement group_id="O4" value="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="269"/>
                    <count group_id="O3" value="573"/>
                    <count group_id="O4" value="579"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2"/>
                    <measurement group_id="O2" value="68.4"/>
                    <measurement group_id="O3" value="66.1"/>
                    <measurement group_id="O4" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3"/>
                    <measurement group_id="O2" value="64.9"/>
                    <measurement group_id="O3" value="54.8"/>
                    <measurement group_id="O4" value="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="362"/>
                    <count group_id="O4" value="375"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2"/>
                    <measurement group_id="O2" value="63.3"/>
                    <measurement group_id="O3" value="66.3"/>
                    <measurement group_id="O4" value="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="503"/>
                    <count group_id="O4" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6"/>
                    <measurement group_id="O2" value="64.5"/>
                    <measurement group_id="O3" value="65.0"/>
                    <measurement group_id="O4" value="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="176"/>
                    <count group_id="O3" value="384"/>
                    <count group_id="O4" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0"/>
                    <measurement group_id="O2" value="69.3"/>
                    <measurement group_id="O3" value="66.4"/>
                    <measurement group_id="O4" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="201"/>
                    <count group_id="O4" value="217"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1"/>
                    <measurement group_id="O2" value="69.1"/>
                    <measurement group_id="O3" value="71.1"/>
                    <measurement group_id="O4" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 232</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6"/>
                    <measurement group_id="O2" value="69.0"/>
                    <measurement group_id="O3" value="65.7"/>
                    <measurement group_id="O4" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline of this LTE study through up to 4.3 years</time_frame>
      <desc>Population included all participants who were enrolled in this study. 1 participant who mistakenly took sirukumab 100mg, when was originally assigned to sirukumab 50mg, was analyzed under the sirukumab 100mg group for all safety analyses. In treatment group 'Placebo to 100 mg q2w Due to EE/LE/CO', 6 deaths happened during the CNTO136ARA3004 study. One additional death was reported in this group after the participant was discontinued from the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo to 50 mg q4w Due to EE/LE/CO</title>
          <description>Participants initially randomized to placebo, then at early escape (EE), late escape (LE), or cross over (CO) randomized to sirukumab 50 mg every 4 weeks (q4w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen (sirukumab 50 mg q4w) upon entering this long-term extension (LTE) study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo to 100 mg q2w Due to EE/LE/CO</title>
          <description>Participants initially randomized to placebo, then at EE, LE, or CO randomized to sirukumab 100 mg every two weeks (q2w) during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
        </group>
        <group group_id="E3">
          <title>Sirukumab 50 mg q4w</title>
          <description>Participants initially randomized to sirukumab 50 mg q4w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
        </group>
        <group group_id="E4">
          <title>Sirukumab 100 mg q2w</title>
          <description>Participants initially randomized to sirukumab 100 mg q2w during the primary studies CNTO136ARA3002 and CNTO136ARA3003, and then continued to receive the same regimen upon entering this LTE study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="160" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="143" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Corneal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Scleritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Gastric volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Soft tissue inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Sphincter of Oddi dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Bursitis infective staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Infective tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Medical device site joint infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Spinal cord infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Streptococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Streptococcal endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Postoperative thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Atlantoaxial instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Finger deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Mixed connective tissue disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Inflammatory pseudotumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Monoclonal gammopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Renal cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Schwannoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Intracranial mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Mononeuropathy multiplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Myxoedema coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ulnar tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Persistent depressive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Cystitis interstitial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Diaphragmatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Penetrating aortic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Vasculitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="268" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="281" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="619"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="605"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="619"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to early study termination, full intended length of observation and amount of safety, efficacy data collected for participants receiving sirukumab was not achieved and only statistical analysis plan dedicated to safety data(Week 28) was created.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Development</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

